NOVOPHARM FORM 1 RANITIDINE IS ONE STEP CLOSER TO MARKET AFTER VICTORY IN ZANTAC PATENT CASE; GLAXO SPECTROSCOPY CLAIMS ARE "IMPOSSIBLE," JUDGE SAYS
Executive Summary
Novopharm has established that it is possible to manufacture Form 1 ranitidine without infringing Glaxo Wellcome's patents for Form 2 of the anti-ulcer agent Zantac, Raleigh, N.C. federal court Judge Terrence Boyle ruled July 5.